Search the Newsreel

The Andover Companies Selects Cognizant to Modernize Technology and Advance AI-Driven Innovation

198-year-old mutual property and casualty insurer to optimize core systems, unify its data and advance responsible AI adoption under a five-year partnership TEANECK, N.J., July 27, 2026 /PRNewswire/ -- Cognizant (Nasdaq: CTSH) announced today a strategic, five-year, enterprise-wide partnership with The Andover Companies, Inc., …

Cognition Therapeutics Inc (CGTX) Balance Sheet

This article provides the quarterly and annual balance sheets for Cognition Therapeutics Inc (CGTX), offering detailed financial data for various assets, liabilities, and shareholder equity components. It also includes an FAQ section that defines key balance sheet metrics and answers specific questions about CGTX's …

Precision Trading with Cognex Corporation (CGNX) Risk Zones

This article analyzes Cognex Corporation (CGNX), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three AI-generated trading strategies: Long Position, Momentum Breakout, and Risk Hedging, with specific entry, target, and stop-loss zones. The analysis emphasizes risk-reward ratios and multi-timeframe …

Alpha Cognition Inc (ACOG) Cash Flow

This article provides a detailed overview of Alpha Cognition Inc's (ACOG) cash flow statements, including operating, investing, and financing activities. It presents quarterly and annual financial figures, along with year-over-year percentage changes for various cash flow components. The report also includes an FAQ section …

Cognition Therapeutics Inc (CGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cognition Therapeutics Inc (CGTX) stock, detailing its performance based on various indicators and moving averages. It highlights the current sell and neutral signals from indicators like MACD and RSI, and predominantly sell signals from moving averages. The …

Alpha Cognition Inc (ACOG) Balance Sheet

This article provides the quarterly and annual balance sheets for Alpha Cognition Inc (ACOG), allowing users to evaluate the company's financial health, analyze fundamentals, and calculate key financial ratios. It details assets, liabilities, and shareholders' equity over several periods, and includes an FAQ section …

Cognizant and Anthropic expand partnership to embed Claude in Cognizant's industry platforms, helping clients close the gap between AI promise and business outcomes

As a Global Premier Partner in the Claude Partner Network, Cognizant brings the industry depth and delivery scale to take Claude from enterprise AI pilots to results in production Cognizant is embedding Claude across its own business and engineering platforms, while scaling a Claude-certified …

Cognex Corp (CGNX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Cognex Corp (CGNX), identifying its major institutional investors and their proportional holdings. It also breaks down shareholder types, institutional shareholding trends over recent quarters, and lists related ETFs that include CGNX in their portfolios.

Cambridge Cognition reports 16% revenue growth in first half By Investing.com

Alpha Cognition Inc (ACOG) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a financial overview of Alpha Cognition Inc (ACOG), focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. Key financial data like market …

OGN|Organon & Co|Price:13.560|

Cognition Therapeutics Inc (CGTX) Income Statement

This article provides the quarterly and annual income statements for Cognition Therapeutics Inc (CGTX), offering detailed financial data such as operating expenses, R&D expenses, operating profit, and net income. It allows for analysis of the company's financial performance and operational efficiency over various periods. …

Cognex Corp (CGNX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article details the historical dividend payouts for Cognex Corp (CGNX), including specific dates for ex-dividend, record, and payment. Over the past five years, the company has distributed a total of $190.59 million in dividends. The information provided outlines interim and final cash dividends …

Alpha Cognition Inc (ACOG) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Alpha Cognition Inc (ACOG), listing its major shareholders and their respective proportions. It also provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in shares held and proportions.

Cognition Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGTX

Sera Prognostics (SERA) Q1 2026 Earnings: In-Line Losses and No Revenue as Stock Declines 5.53% - Post-Announcement Reaction

ACOG|Alpha Cognition Inc|Price:7.900|Chg%:-0.330

Alpha Cognition Inc. (ACOG) closed at $7.90, down 4.01%, with a market cap of $172.02M. The company, focused on neurodegenerative disease treatments, is rated "Buy" by analysts with a target price of $16.00, representing a 94.41% upside. Its fundamentals are strong, and its valuation …

Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. (NYSE:OGN). The investigation focuses on whether Organon and its officers engaged in corporate wrongdoing, specifically for investors who purchased Organon securities before November 3, 2022, and continue …

CGTX|Cognition Therapeutics Inc|Price:0.929|Chg%:+0.010

Cognition Therapeutics Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina. The company's lead candidate, zervimesine (CT1812), is in clinical programs for dementia with Lewy bodies (DLB) and Alzheimer’s …

Organon & Co. (1OGN) Q4 2025 Earnings Report - Results, Call & Slides

Organon & Co. reported Q4 2025 earnings, missing both EPS and revenue expectations with actual EPS of €0.55 against consensus €0.64 and actual revenue of €1.32 billion against an expected €1.35 billion. The company provided a neutral outlook, guiding for roughly flat revenue and …

Cognex Corporation Revenue Breakdown – NASDAQ:CGNX

Alpha Cognition Inc. (ACOG) sees 200,086-share buy by 10% holder

Opaleye Management Inc., a ten percent owner of Alpha Cognition Inc. (ACOG), indirectly purchased a total of 200,086 common shares on July 22–23, 2026. These shares were acquired for Opaleye, L.P. and a separately managed account at weighted average prices of $7.8337 and $7.7953 …

Cognizant (CTSH) Stock Looks Reasonable On Earnings Despite Weak Returns

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Cognizant Technology Solutions stock has fallen about 47.1% year to date, yet its valuation checks still lean cheap, which sets up a clear tension between …

Organon & Co. Shareholders Clear Sun Pharma Merger Deal

Organon & Co. shareholders have approved the proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a special virtual meeting. Shareholders also passed a non-binding advisory vote regarding compensation for executive officers in connection with the merger. The final voting results will be …

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD®) and ≥75% improvement in Eczema Area and Severity …

Organon's VTAMA Skin-Clearance Response Reached 56.3% in Ages 2–6 at Week 8

Organon (NYSE: OGN) announced new data from a post hoc analysis of its Phase 3 ADORING 1 and 2 trials for VTAMA cream, showing early and consistent improvements in atopic dermatitis across pediatric age groups and adults. The cream demonstrated significant skin clearance and …

Cognizant (CTSH) Could Be Near A Growth Turnaround As Q2 Results Loom

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Cognizant Technology Solutions is set to report Q2 results that some analysts see as the start of a major turnaround in its growth profile. …

CGNT|Cognyte Software Ltd|Price:8.300|Chg%:+0.110

This article provides a detailed financial overview and analysis of Cognyte Software Ltd (CGNT), an Israel-based company specializing in security and analytics software. It highlights the company's strong fundamentals and high growth potential, despite a forecasted medium-term downward trend in stock price. The analysis …

Cognizant and Gulf Edge Launch Strategic AI & Services Partnership to Accelerate Thailand's AI Transformation

Partnership combines sovereign digital infrastructure, enterprise AI capabilities, and industry expertise to help position Thailand as a leading AI economy in Southeast Asia BANGKOK and TEANECK, N.J., July 23, 2026 /PRNewswire/ -- Cognizant (Nasdaq: CTSH), a leading AI builder and global technology services provider, …

Cognizant and Gulf Edge Announce Strategic Partnership to Accelerate Enterprise AI Adoption in Southeast Asia

Gulf Development Public Company Limited (GULF) Partnership combines Cognizant's global AI engineering capabilities with Gulf Edge's sovereign digital infrastructure to capture the region's growing demand for secure, scalable AI solutions.From left to right: 1. Mr. Thomas Mathew, Vice President, Head of ASEAN and Greater …

Organon (OGN) Stock Looks Below Fair Value Despite Weak Earnings Quality

Cognyte Software Ltd. (81M) Q1 2026 Earnings Report - Results, Call & Slides

Cognyte Software Ltd. (81M) has released its Q1 2026 earnings report, showing an actual EPS of €0.06, beating the consensus of <€0.01. The company also reported actual revenue of €83.68M, surpassing the expected €82.29M, with a YoY revenue growth of 15.52%. The next earnings …

Organon (OGN) Names A Canada Chief, Is The Stock Cheap?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Leadership change in Canada puts Organon (OGN) in focus Organon (OGN) is back on investors' radar after Organon Canada appointed Dominic Bégin as President and Managing Director, …

(CGNT) Risk Channels and Responsive Allocation

A quantitative research report on Cognyte Software Ltd. (NASDAQ: CGNT) highlights weak near-term sentiment but identifies an exceptional 67.5:1 risk-reward setup targeting a 17.5% gain with only 0.3% risk. The analysis provides three distinct AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored …

Cognition Therapeutics (CGTX) Q2 2024 earnings summary

Cognition Therapeutics (CGTX) announced its Q2 2024 earnings, highlighting progress in its Phase 2 trials for CT-1812 in Alzheimer's, dementia with Lewy bodies (DLB), and dry AMD. The company reported a 39% slowing of cognitive decline in its SHINE Alzheimer's trial and expects topline …

ACOG Options Chain — NASDAQ:ACOG

This article from TradingView provides an overview of the options chain for Alpha Cognition Inc. (ACOG) on the NASDAQ stock market. It highlights features like contract overview, chain volatility, and data for both call and put options, helping users track market movements and assess …